维生素D补充剂在糖尿病中调节糖化血红蛋白 (HBA1c)
Asma Akhter1, Sultan Alouffi2, Uzma Shahab3
1Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, 11790, United States.
Archives of biochemistry and biophysics
|January 27, 2024
概括
维生素D不足与糖尿病患者的HbA1c水平较高有关. 本综述探讨了维生素D补充剂的使用情况.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 营养科学 营养科学
背景情况:
- 糖尿病是一种代谢障碍,其特征是高血糖和蛋白质糖化增加.
- 先进糖化终产品 (RAGE) 受体压力与糖尿病病因有关.
- 维生素D除了对骨的好处之外,在免疫和代谢功能中也有潜在的作用.
研究的目的:
- 为了检查维生素D补充剂和糖尿病患者的HbA1c水平之间的关系.
- 讨论维生素D对血糖控制的影响的生物可信性.
主要方法:
- 审查现有的横截面,前性观察性研究和临床试验.
- 对维生素D水平,补充剂和血糖标记物 (HbA1c) 的数据分析.
主要成果:
- 维生素D缺乏与较高的HbA1c,代谢综合征和糖尿病有关.
- 观察性研究表明,维生素D水平与2型糖尿病中HbA1c升高之间存在反向关系.
- 对维生素D补充剂用于血糖控制的临床试验产生了不同的结果.
结论:
- 维生素D状态和糖尿病管理之间存在潜在的联系.
- 需要进一步的研究来澄清维生素D补充剂改善糖尿病血糖控制的疗效.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Hormones Regulating Blood Glucose
3.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.4K
Insulin: Dosing Regimen and Adverse Effects
174
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
174
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
Dipeptidyl Peptidase 4 Inhibitors
187
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
187


